ReviewExpert review of anti-infective therapy2010
Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.
Review in Expert review of anti-infective therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Dose optimization of vancomycin in obese patients: A systematic review.Frontiers in pharmacology · 2023Pooled it
- Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Multimodal data-driven predictive model for vancomycin serum concentrations in postoperative cardiac surgery patients under cardiopulmonary bypass: a single-center retrospective study.Frontiers in pharmacology · 2025Article
- Development of an on-site therapeutic drug monitoring method using a portable spectrometer.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Population Pharmacokinetics and Dosing Optimization of Norvancomycin for Chinese Patients with Community-Acquired Pneumonia.Infection and drug resistance · 2024Article
- Population pharmacokinetics of vancomycin in patients with diabetic foot infection: a comparison of five models.Journal of diabetes and metabolic disorders · 2023Article
- Antimicrobial-loaded biodegradable nanoemulsions for efficient clearance of intracellular pathogens in bacterial peritonitis.Biomaterials · 2023Article
- Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: A simulation study.Clinical and translational science · 2023Article
- Discrepancy between perceptions and acceptance of clinical decision support Systems: implementation of artificial intelligence for vancomycin dosing.BMC medical informatics and decision making · 2023Article
- Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Vancomycin in Patients with External Ventricular Drain.Antimicrobial agents and chemotherapy · 2023Observational
- Article
- Review
- Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus.Communications biology · 2021Article
- Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.Frontiers in pharmacology · 2020Article
- High sensitivity versus low level of vancomycin needs to be concern for another alternative anti- Staphylococcus aureus as the first- line antibiotic.Acta bio-medica : Atenei Parmensis · 2019Article
- Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore.International journal of clinical pharmacy · 2018Article
- Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis.Infection and drug resistance · 2018Review
- Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol.Infectious diseases and therapy · 2017Review
- Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.Veterinary sciences · 2017Review
- Comment on "Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction".BioMed research international · 2017Article
Corrections and comments
- Erratum issuedGiulano, Christopher [corrected to Giuliano, Christopher]
Authors and funding
4 authors.
Funding
Abstract
Vancomycin is a commonly used antimicrobial in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Increasing vancomycin MIC values in MRSA clinical isolates makes the optimization of vancomycin dosing pivotal to its continued use. Unfortunately, limited data exist regarding the optimal pharmacokinetic-pharmacodynamic (PK-PD) goal to improve bacterial killing and clinical outcomes with vancomycin. The hallmark study in this area suggests that achieving an AUC to MIC ratio of over 400 improves the likelihood of achieving these outcomes. Challenges in the implementation of PK-PD-based dosing for vancomycin include current methodologies utilized in microbiology laboratories, as well as intra- and interpatient pharmacokinetic variability. Individualized dosing based on MIC and specific patient factors is important to achieve optimal outcomes from vancomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.